What's Happening?
Arcturus Therapeutics Holdings Inc., a San Diego-based mRNA medicines company, has announced its financial results for the fourth quarter and fiscal year 2025. The company, known for its development of liver and respiratory rare disease therapeutics,
reported a net loss of $65.8 million for the year, a decrease from the previous year's loss of $80.9 million. Revenue for 2025 was $82.0 million, down from $152.3 million in 2024, primarily due to reduced activity in its CSL collaboration. Despite these financial challenges, Arcturus has extended its cash runway into the second quarter of 2028. The company is advancing its ARCT-032, a once-daily inhaled mRNA therapeutic for cystic fibrosis, into a 12-week Phase 2 study set to begin in the first half of 2026. Additionally, Arcturus is expanding its ARCT-810 program for ornithine transcarbamylase deficiency and continues to develop a self-amplifying mRNA pandemic influenza vaccine under a contract with BARDA.
Why It's Important?
The financial results and strategic advancements of Arcturus Therapeutics are significant for the biotechnology sector, particularly in the field of mRNA therapeutics. The company's focus on rare diseases and its innovative mRNA technology platforms position it as a key player in the development of new treatments for conditions with limited options. The extension of its cash runway into 2028 provides financial stability, allowing continued investment in its pipeline. The progression of ARCT-032 into Phase 2 trials is crucial for cystic fibrosis patients, offering potential new treatment options. Furthermore, the development of a pandemic influenza vaccine highlights Arcturus's role in addressing global health challenges, which could have broad implications for public health preparedness and response.
What's Next?
Arcturus plans to initiate the 12-week Phase 2 study for ARCT-032 in the first half of 2026, enrolling up to 20 participants with cystic fibrosis. The study will assess safety and early clinical benefits, including lung function improvements. The company is also preparing for regulatory interactions to support pivotal studies for its ARCT-810 program, targeting both pediatric and adult populations with ornithine transcarbamylase deficiency. Additionally, Arcturus's ongoing lawsuit against AbbVie Inc. and Capstan Therapeutics, Inc. remains a point of interest, potentially impacting its strategic direction and financial outcomes.
